FOXP1 directly represses transcription of proapoptotic genes and cooperates with NF-κB to promote survival of human B cells

Blood

Volumn 124, Issue 23, 2014, Pages 3431-3440

  Van Keimpema, Martine ^a   Grüneberg, Leonie J ^a   Mokry, Michal ^b   Van Boxtel, Ruben ^c   Koster, Jan ^d   Coffer, Paul J ^c   Pals, Steven T ^a   Spaargaren, Marcel ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^d UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AIM2 PROTEIN; BH3 PROTEIN; EAF2 PROTEIN; FORKHEAD TRANSCRIPTION FACTOR; FORKHEAD TRANSCRIPTION FACTOR FOXP1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN; PROTEIN P53; RASSF6 PROTEIN; RITUXIMAB; TP53INP1 PROTEIN; TP63 PROTEIN; UNCLASSIFIED DRUG; APOPTOSIS REGULATORY PROTEIN; FOXP1 PROTEIN, HUMAN; REPRESSOR PROTEIN;

APOPTOSIS; ARTICLE; B CELL LYMPHOMA; B LYMPHOCYTE; CELL EXPANSION; CELL PROLIFERATION; CELL SURVIVAL; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; GENE EXPRESSION; GENE OVEREXPRESSION; GENE REPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; IN VITRO STUDY; MARGINAL ZONE LYMPHOMA; MICROARRAY ANALYSIS; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; CELL CULTURE; CELL TRANSFORMATION; DOWN REGULATION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; GENETICS; LARGE CELL LYMPHOMA; METABOLISM; PATHOLOGY; PHYSIOLOGY; UPREGULATION;

APOPTOSIS REGULATORY PROTEINS; B-LYMPHOCYTES; CELL SURVIVAL; CELL TRANSFORMATION, NEOPLASTIC; CELLS, CULTURED; DOWN-REGULATION; FORKHEAD TRANSCRIPTION FACTORS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MICROARRAY ANALYSIS; NF-KAPPA B; REPRESSOR PROTEINS; TRANSCRIPTION, GENETIC; UP-REGULATION;

EID: 84914093951     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2014-01-553412     Document Type: Article

References (73)

1. Feng X, Ippolito GC, Tian L, et al. Foxp1 is an essential transcriptional regulator for the generation of quiescent naive T cells during thymocyte development. Blood. 2010;115(3): 510-518.
2. Feng X, Wang H, Takata H, Day TJ, Willen J, Hu H. Transcription factor Foxp1 exerts essential cellintrinsic regulation of the quiescence of naive T cells. Nat Immunol. 2011;12(6):544-550.
3. Hu H, Wang B, Borde M, et al. Foxp1 is an essential transcriptional regulator of B cell development. Nat Immunol. 2006;7(8):819-826.
4. Rao DS, O'Connell RM, Chaudhuri AA, Garcia-Flores Y, Geiger TL, Baltimore D. MicroRNA-34a perturbs B lymphocyte development by repressing the forkhead box transcription factor Foxp1. Immunity. 2010;33(1):48-59.
5. Sagardoy A, Martinez-Ferrandis JI, Roa S, et al. Downregulation of FOXP1 is required during germinal center B-cell function. Blood. 2013; 121(21):4311-4320.
6. Koon HB, Ippolito GC, Banham AH, Tucker PW. FOXP1: a potential therapeutic target in cancer. Expert Opin Ther Targets. 2007;11(7):955-965.
7. Katoh M, Igarashi M, Fukuda H, Nakagama H, Katoh M. Cancer genetics and genomics of human FOX family genes. Cancer Lett. 2013; 328(2):198-206.
8. Banham AH, Connors JM, Brown PJ, et al. Expression of the FOXP1 transcription factor is strongly associated with inferior survival in patients with diffuse large B-cell lymphoma. Clin Cancer Res. 2005;11(3):1065-1072.
9. Sagaert X, de Paepe P, Libbrecht L, et al. Forkhead box protein P1 expression in mucosaassociated lymphoid tissue lymphomas predicts poor prognosis and transformation to diffuse large B-cell lymphoma. J Clin Oncol. 2006;24(16): 2490-2497.
10. Streubel B, Vinatzer U, Lamprecht A, Raderer M, Chott A. T(3;14)(p14.1;q32) involving IGH and FOXP1 is a novel recurrent chromosomal aberration in MALT lymphoma. Leukemia. 2005; 19(4):652-658.
11. Fenton JA, Schuuring E, Barrans SL, et al. t(3;14)(p14;q32) results in aberrant expression of FOXP1 in a case of diffuse large B-cell lymphoma. Genes Chromosomes Cancer. 2006;45(2):164-168.
12. Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004;103(1):275-282.
13. Staudt LM, Dave S. The biology of human lymphoid malignancies revealed by gene expression profiling. Adv Immunol. 2005;87: 163-208.
14. Lenz G, Wright GW, Emre NC, et al. Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways. Proc Natl Acad Sci USA. 2008;105(36):13520-13525.
15. Craig VJ, Cogliatti SB, Imig J, et al. Myc-mediated repression of microRNA-34a promotes high-grade transformation of B-cell lymphoma by dysregulation of FoxP1. Blood. 2011;117(23): 6227-6236.
16. Staudt LM. Oncogenic activation of NF-kappaB. Cold Spring Harb Perspect Biol. 2010;2(6): a000109.
17. Thome M. CARMA1, BCL-10 and MALT1 in lymphocyte development and activation. Nat Rev Immunol. 2004;4(5):348-359.
18. Bende RJ, Aarts WM, Riedl RG, de Jong D, Pals ST, van Noesel CJ. Among B cell non-Hodgkin's lymphomas, MALT lymphomas express a unique antibody repertoire with frequent rheumatoid factor reactivity. J Exp Med. 2005;201(8): 1229-1241.
19. Compagno M, Lim WK, Grunn A, et al. Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma. Nature. 2009;459(7247):717-721.
20. Davis RE, Ngo VN, Lenz G, et al. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature. 2010;463(7277):88-92.
21. Shaffer AL III, Young RM, Staudt LM. Pathogenesis of human B cell lymphomas. Annu Rev Immunol. 2012;30:565-610.
22. Lenz G, Davis RE, Ngo VN, et al. Oncogenic CARD11 mutations in human diffuse large B cell lymphoma. Science. 2008;319(5870):1676-1679.
23. Kraan W, van Keimpema M, Horlings HM, et al. High prevalence of oncogenic MYD88 and CD79B mutations in primary testicular diffuse large B-cell lymphoma. Leukemia. 2014;28(3):719-720.
24. Kraan W, Horlings HM, van Keimpema M, et al. High prevalence of oncogenic MYD88 and CD79B mutations in diffuse large B-cell lymphomas presenting at immune-privileged sites. Blood Cancer J. 2013;3:e139.
25. Shi C, Zhang X, Chen Z, et al. Integrin engagement regulates monocyte differentiation through the forkhead transcription factor Foxp1. J Clin Invest. 2004;114(3):408-418.
26. Scheeren FA, Naspetti M, Diehl S, et al. STAT5 regulates the self-renewal capacity and differentiation of human memory B cells and controls Bcl-6 expression. Nat Immunol. 2005; 6(3):303-313.
27. Arpin C, Déchanet J, Van Kooten C, et al. Generation of memory B cells and plasma cells in vitro. Science. 1995;268(5211):720-722.
28. Diehl SA, Schmidlin H, Nagasawa M, et al. STAT3-mediated up-regulation of BLIMP1 Is coordinated with BCL6 down-regulation to control human plasma cell differentiation. J Immunol. 2008;180(7):4805-4815.
29. Kwakkenbos MJ, Diehl SA, Yasuda E, et al. Generation of stable monoclonal antibodyproducing B cell receptor-positive human memory B cells by genetic programming. Nat Med. 2010; 16(1):123-128.
30. Tjin EPM, Groen RWJ, Vogelzang I, et al. Functional analysis of HGF/MET signaling and aberrant HGF-activator expression in diffuse large B-cell lymphoma. Blood. 2006;107(2):760-768.
31. Ding BB, Yu JJ, Yu RYL, et al. Constitutively activated STAT3 promotes cell proliferation and survival in the activated B-cell subtype of diffuse large B-cell lymphomas. Blood. 2008;111(3): 1515-1523.
32. Kocemba KA, van Andel H, de Haan-Kramer A, et al. The hypoxia target adrenomedullin is aberrantly expressed in multiple myeloma and promotes angiogenesis. Leukemia. 2013;27(8): 1729-1737.
33. van Boxtel R, Gomez-Puerto C, Mokry M, et al. FOXP1 acts through a negative feedback loop to suppress FOXO-induced apoptosis. Cell Death Differ. 2013;20(9):1219-1229.
34. Rampanelli E, Dessing MC, Claessen N, et al. CD44-deficiency attenuates the immunologic responses to LPS and delays the onset of endotoxic shock-induced renal inflammation and dysfunction. PLoS ONE. 2013;8(12):e84479.
35. Guikema JEJ, Gerstein RM, Linehan EK, et al. Apurinic/apyrimidinic endonuclease 2 is necessary for normal B cell development and recovery of lymphoid progenitors after chemotherapeutic challenge. J Immunol. 2011; 186(4):1943-1950.
36. Gabut M, Samavarchi-Tehrani P, Wang X, et al. An alternative splicing switch regulates embryonic stem cell pluripotency and reprogramming. Cell. 2011;147(1):132-146.
37. Visco C, Li Y, Xu-Monette ZY, et al. Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP Consortium Program Study. Leukemia. 2012;26(9):2103-2113.
38. Yang Y, Shaffer AL III, Emre NC, et al. Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma. Cancer Cell. 2012;21(6): 723-737.
39. Rudra D, deRoos P, Chaudhry A, et al. Transcription factor Foxp3 and its protein partners form a complex regulatory network. Nat Immunol. 2012;13(10):1010-1019.
40. Samstein RM, Arvey A, Josefowicz SZ, et al. Foxp3 exploits a pre-existent enhancer landscape for regulatory T cell lineage specification. Cell. 2012;151(1):153-166.
41. Berberich I, Shu GL, Clark EA. Cross-linking CD40 on B cells rapidly activates nuclear factorkappa B. J Immunol. 1994;153(10):4357-4366.
42. Good KL, Bryant VL, Tangye SG. Kinetics of human B cell behavior and amplification of proliferative responses following stimulation with IL-21. J Immunol. 2006;177(8):5236-5247.
43. Lømo J, Blomhoff HK, Beiske K, Stokke T, Smeland EB. TGF-beta 1 and cyclic AMP promote apoptosis in resting human B lymphocytes. J Immunol. 1995;154(4): 1634-1643.
44. van Dongen JJ, Langerak AW, Brüggemann M, et al. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4- CT98-3936. Leukemia. 2003;17(12):2257-2317.
45. Harnett MM. CD40: a growing cytoplasmic tale. Sci STKE. 2004;2004(237):pe25.
46. Bishop GA. The multifaceted roles of TRAFs in the regulation of B-cell function. Nat Rev Immunol. 2004;4(10):775-786.
47. Kaileh M, Sen R. NF-κB function in B lymphocytes. Immunol Rev. 2012;246(1): 254-271.
48. Sasaki Y, Derudder E, Hobeika E, et al. Canonical NF-kappaB activity, dispensable for B cell development, replaces BAFF-receptor signals and promotes B cell proliferation upon activation. Immunity. 2006;24(6):729-739.
49. Calado DP, Zhang B, Srinivasan L, et al. Constitutive canonical NF-kB activation cooperates with disruption of BLIMP1 in the pathogenesis of activated B cell-like diffuse large cell lymphoma. Cancer Cell. 2010;18(6):580-589.
50. Klein U, Tu Y, Stolovitzky GA, et al. Transcriptional analysis of the B cell germinal center reaction. Proc Natl Acad Sci USA. 2003; 100(5):2639-2644.
51. Spender LC, O'Brien DI, Simpson D, et al. TGF-beta induces apoptosis in human B cells by transcriptional regulation of BIK and BCL-XL. Cell Death Differ. 2009;16(4):593-602.
52. Jiang A, Clark EA. Involvement of Bik, a proapoptotic member of the Bcl-2 family, in surface IgM-mediated B cell apoptosis. J Immunol. 2001;166(10):6025-6033.
53. Saltzman A, Munro R, Searfoss G, Franks C, Jaye M, Ivashchenko Y. Transforming growth factor-beta-mediated apoptosis in the Ramos B-lymphoma cell line is accompanied by caspase activation and Bcl-XL downregulation. Exp Cell Res. 1998;242(1):244-254.
54. Srinivasan L, Sasaki Y, Calado DP, et al. PI3 kinase signals BCR-dependent mature B cell survival. Cell. 2009;139(3):573-586.
55. Chen L, Monti S, Juszczynski P, et al. SYK inhibition modulates distinct PI3K/AKTdependent survival pathways and cholesterol biosynthesis in diffuse large B cell lymphomas. Cancer Cell. 2013;23(6):826-838.
56. Xu-Monette ZY, Medeiros LJ, Li Y, et al. Dysfunction of the TP53 tumor suppressor gene in lymphoid malignancies. Blood. 2012;119(16): 3668-3683.
57. Su X, Chakravarti D, Flores ER. p63 steps into the limelight: crucial roles in the suppression of tumorigenesis and metastasis. Nat Rev Cancer. 2013;13(2):136-143.
58. Iwasa H, Kudo T, Maimaiti S, et al. RASSF6 tumor suppressor regulates apoptosis and cell cycle via MDM2 and p53. J Biol Chem. 2013;288: 30320-30329.
59. Shahbazi J, Lock R, Liu T. Tumor protein 53- induced nuclear protein 1 (TP53INP1) enhances p53 function and represses tumorigenesis. Front Genet. 2013;4:80.
60. Fukushima N, Satoh T, Sueoka N, et al. Clinico-pathological characteristics of p63 expression in B-cell lymphoma. Cancer Sci. 2006;97(10): 1050-1055.
61. Hallack Neto AE, Siqueira SAC, Dulley FL, Ruiz MA, Chamone DA, Pereira J. p63 protein expression in high risk diffuse large B-cell lymphoma. J Clin Pathol. 2009;62(1):77-79.
62. Saito Y, Suzuki H, Tsugawa H, et al. Overexpression of miR-142-5p and miR-155 in gastric mucosa-associated lymphoid tissue (MALT) lymphoma resistant to Helicobacter pylori eradication. PLoS ONE. 2012;7(11):e47396.
63. Hesson LB, Dunwell TL, Cooper WN, et al. The novel RASSF6 and RASSF10 candidate tumour suppressor genes are frequently epigenetically inactivated in childhood leukaemias. Mol Cancer. 2009;8(1):42.
64. Shinawi T, Hill V, Dagklis A, et al. KIBRA gene methylation is associated with unfavorable biological prognostic parameters in chronic lymphocytic leukemia. Epigenetics. 2012;7(3): 211-215.
65. Kuo TC, Shaffer AL, Haddad J Jr, Choi YS, Staudt LM, Calame K. Repression of BCL-6 is required for the formation of human memory B cells in vitro. J Exp Med. 2007;204(4):819-830.
66. Ngo VN, Young RM, Schmitz R, et al. Oncogenically active MYD88 mutations in human lymphoma. Nature. 2011;470(7332):115-119.
67. Sen R. Control of B lymphocyte apoptosis by the transcription factor NF-kappaB. Immunity. 2006; 25(6):871-883.
68. Vallabhapurapu S, Karin M. Regulation and function of NF-kappaB transcription factors in the immune system. Annu Rev Immunol. 2009;27(1): 693-733.
69. Aalipour A, Advani RH. Bruton tyrosine kinase inhibitors: a promising novel targeted treatment for B cell lymphomas. Br J Haematol. 2013; 163(4):436-443.
70. Wilson WH, Gerecitano JF, Goy A, et al. The Bruton's tyrosine kinase (BTK) inhibitor, ibrutinib (PCI-32765), has preferential activity in the ABC subtype of relapsed/refractory de novo diffuse B-cell lymphoma (DLBCL): interim results of a multicenter, open-label, phase 2 study [abstract]. Blood. 2012;120(21):686.
71. Lim KH, Romero DL, Chaudhary D, Robinson SD, Staudt LM. IRAK4 kinase as a novel therapeutic target in the ABC subtype of diffuse B cell lymphoma [abstract]. Blood. 2012;120(21):62.
72. Fontan L, Yang C, Kabaleeswaran V, et al. MALT1 small molecule inhibitors specifically suppress ABC-DLBCL in vitro and in vivo. Cancer Cell. 2012;22(6):812-824.
73. Nagel D, Spranger S, Vincendeau M, et al. Pharmacologic inhibition of MALT1 protease by phenothiazines as a therapeutic approach for the treatment of aggressive ABC-DLBCL. Cancer Cell. 2012;22(6):825-837.